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Anticoagulation represents the mainstay of therapy for most patients with atrial ﬁbrillation. Patients on oral anticoagulation
often require concomitant antiplatelet therapy, mostly because of coronary artery disease. After coronary stent implantation, dual
antiplatelet therapy is necessary. However, the combination of oral anticoagulation and antiplatelet therapy increases the bleeding
risk. Risk scores such as the CHA2DS2-Vasc score and the HAS-BLED score help to identify both bleeding and stroke risk in
individual patients. The guidelines of the European Society of Cardiology provide a rather detailed recommendation for patients
on oral anticoagulation after coronary stent implantation. However, robust evidence is lacking for some of the recommendations,
and especially for new oral anticoagulants and new antiplatelets few or no data are available. This review addresses some of the
critical points of the guidelines and discusses potential advantages of new anticoagulants in patients with atrial ﬁbrillation after
stent implantation.
1.Introduction
Both patients with coronary artery disease as well as patients
with atrial ﬁbrillation frequently require antiplatelet therapy
or anticoagulation to reduce the risk of cardiovascular and
cerebral events. Recently, a number of new antiplatelet drugs
and new drugs for anticoagulation have been approved to
expand the armory of the treating physician. The standard
antithrombotic agent for patients with coronary artery dis-
ease is aspirin; usually a dual therapy with addition of clopi-
dogrel or newer agents is required after stent implantation
or acute coronary syndrome. In patients with chronic atrial
ﬁbrillation, oral anticoagulation with vitamin K-antagonists
represents the mainstay of therapy. In patients presenting
with both coronary artery disease and atrial ﬁbrillation, the
choice of medication is sometimes challenging, especially
with respect to a possible increase in bleeding complications
in patients treated with a dual or triple therapy.
2. Risk Assessment inAtrial Fibrillation
ThecurrentguidelinesoftheEuropeanSocietyofCardiology
(ESC) for atrial ﬁbrillation suggest risk stratiﬁcation in
patients with nonvalvular atrial ﬁbrillation for the decision
of implementing oral anticoagulation [1]. This risk stratiﬁ-
cation is based on the CHADS2- and CHA2DS2-Vasc-Score
[1]. The CHA2DS2-Vasc-Score is depicted in Table 1. These
scores can easily be implemented into clinical routine as they
are simple, although they do not take into account other
risk factors such as left atrial ﬂow velocity or the diﬀerent
odds ratios of the included risk factors, with exception of a
higher weight of previous stroke and high age (attribution of
2 points).
Numerous studies have demonstrated the superiority
of oral anticoagulation compared to antiplatelet therapy in
patients with atrial ﬁbrillation and an increased risk for
cerebrovascular events [2]. Thus, in patients with major2 Thrombosis
Table 1: CHA2DS2-Vasc-Score [1].
Points
C Congestive heart failure 1
H Hypertension 1
AA g e ≥ 75 years 2
DD i a b e t e s m e l l i t u s 1
S Stroke/TIA/thromboembolism 2
V Vascular disease 1
A Age 65–74 years 1
S Sex category (female sex) 1
max. 9
Table 2: HAS-BLED Score [1].
Points
H Hypertension 1
A Abnormal renal and liver function
(1 point each) 1o r2
SS t r o k e 1
B Bleeding 1
LL a b i l e I N R s 1
E Elderly (e.g., ≥65 years) 1
D Drugs or alcohol (1 point each) 1 or 2
max. 9
Hypertension:systolicbloodpressure >160mmHg.Abnormalkidneyfunc-
tion: chronic dialysis or renal transplantation or creatinine ≥ 200mmol/L.
Abnormal liver function: chronic hepatic disease (e.g., cirrhosis) or
biochemical evidence of signiﬁcant hepatic derangement (e.g., bilirubin
> 2x upper limit of normal, in association with aspartate aminotrans-
ferase/alanine aminotransferase/alkaline phosphatase > 3x upper limit
normal, etc.). Bleeding: previous bleeding history and/or predisposition to
bleeding, for example, bleeding diathesis, anaemia, and so forth. Labile
INRs: unstable/high INRs or poor time in therapeutic range (e.g., <60%).
Drugs/alcohol use: concomitant use of drugs, such as antiplatelet agents,
nonsteroidal anti-inﬂammatory drugs, or alcohol abuse, and so forth INR:
international normalized ratio.
risk factors, such as previous stroke, and in patients with
two or more nonmajor risk factors, oral anticoagulation is
recommended [1]. In patients with only one nonmajor risk
factor, oral anticoagulation is also the preferred therapy;
alternatively aspirin (75–325mg/d) should be used. Thus,
the majority of patients with atrial ﬁbrillation requires oral
anticoagulation [3, 4]. In patients without risk factors, the
preferred treatment is no antithrombotic therapy rather
than aspirin [1]. However, anticoagulation with vitamin K-
antagonists is widely underused in clinical practise, partly
due to disadvantages of vitamin-K-antagonists such as
cumbersome INR-monitoring or drug interactions [5].
Anticoagulation is associated with an increased risk
of bleeding. The ESC guidelines on atrial ﬁbrillation also
provide a risk score to assess the haemorrhagic risk: the
HAS-BLED-Score (Table 2)[ 1]. However, some factors, for
example, increased age, are associated with an increased risk
for stroke as well as an increased risk for bleeding.
Table 3: ESC Anticoagulation regimen in patients with low-
intermediate bleeding risk after stent implantation [1].
Setting stent Anticoagulation (HAS-BLED 0–2)
Elective BMS 1 month: VKA + aspirin + clopidogrel
Lifelong: VKA
Elective DES
3∗ months: VKA + aspirin + clopidogrel
Up to 12th month: VKA + clopidogrel (or aspirin)
Lifelong: VKA
ACS
BMS/DES
6 months: VKA + aspirin+clopidogrel
Up to 12th month: VKA + clopidogrel (oraspirin)
Lifelong: VKA
ACS: acute coronary syndrome, BMS: bare metal stent, DES: drug eluting
stent, VKA: vitamin K-antagonist, ∗6 months in patients with a paclitaxel-
eluting stent. The INR should be adjusted according to concomitant
antiplatelet therapy (2-3 in vitamin K-antagonist monotherapy and 2–2.5 in
case of concomitant antiplatelet therapy).
3. Antithrombotic Therapy after
S t e ntI m p l antatio ninP atie nts
with Atrial Fibrillation
A practical approach to the management of patients with
atrial ﬁbrillation who need oral anticoagulation after coro-
nary artery stenting is presented in the current ESC guide-
lines for atrial ﬁbrillation [1]. These recommendations are
depicted in Table 3 for patients with a low or intermediate
risk of bleeding and in Table 4 for patients with a high risk of
bleeding. Basically, a triple therapy consisting of a vitamin-
K-antagonist, aspirin, and clopidogrel is recommended for
a short period of time and a vitamin-K-antagonist alone
as lifelong therapy. Depending on the clinical presentation
(acute coronary syndrome versus elective stenting), the
hemorrhagic risk and the type of stent used (drug eluting
versus bare metal stent), the recommended duration of triple
therapy varies between 2 weeks and 6 months, and a dual
therapyconsistingofavitamin-K-antagonistandclopidogrel
might be used after the triple therapy for up to 12 months
after stenting.
These recommendations can be used as a “roadmap”
for the management of patients with atrial ﬁbrillation
and coronary stenting especially because they are detailed
and pragmatic. However, these recommendations are based
mainly on small studies, retrospective analyses, or expert
opinion.
Ad i ﬀerent, less detailed decision algorithm has been
suggested by Paikin et al. in Circulation [6]. In contrast
to the ESC guidelines, oral anticoagulation is temporarily
withheld in patients with a high risk of bleeding and a high
thromboembolic risk (Table 5). According to this algorithm,
triple therapy is primarily used in patients with a high
thromboembolic and low bleeding risk. In conclusion, this
algorithm is thus less aggressive in anticoagulation therapy
than the ESC suggestion.
In a large Danish registry including more than 40.000
patients with myocardial infarction, yearly bleeding rates inThrombosis 3
Table 4: ESC Anticoagulation regimen in patients with high
bleeding risk after stent implantation [1].
Setting stent Anticoagulation (HAS-BLED ≥ 3)
Elective BMS# 2–4 weeks: VKA + aspirin + clopidogrel
Lifelong: VKA
ACS BMS#
4 weeks: VKA + aspirin+ clopidogrel
Up to 12th month: VKA + clopidogrel
(oraspirin)
Lifelong: VKA
ACS: acute coronary syndrome, BMS: bare metal stent, DES: drug eluting
stent,VKA:vitaminK-antagonist, #DESshouldbea v oidedasfaraspossible;
if used, triple therapy might be prolonged to 3–6 months. The INR should
be adjusted according to concomitant antiplatelet therapy (2-3 in vitamin
K-antagonist monotherapy and 2–2.5 in case of concomitant antiplatelet
therapy).
Table 5: U. S. Anticoagulation regimen after stent implantation
(adopted from Paikin et al.) [6].
Setting Anticoagulation/Antiplatelets
CHADS2 0-1 Aspirin + clopidogrel
CHADS2 > 1, low bleeding
risk Aspirin + clopidogrel + warfarin
CHADS2 > 1, high bleeding
risk Aspirin + clopidogrel
CHADS2: cardiac failure, hypertension, age, diabetes, stroke (doubled).
High risk of bleeding: for example, age > 75 year, severe renal dysfunction,
recent gastrointestinal bleeding, prior stroke, uncontrolled hypertension.
Bare metal stents should be preferred, the duration of triple therapy months
should be restricted to 1 month after bare metal stent implantation and 3
after drug eluting stent implantation (6 months in paclitaxel stents).
patientsreceivingtripletherapy(aspirin+clopidogrel+vita-
min K antagonist) or dual therapy consisting of clopidogrel
andvitaminKantagonistwere12%[7].Incontrast,bleeding
rates for monotherapy (aspirin, clopidogrel, or vitamin K
antagonist) and dual therapy with aspirin and vitamin K
antagonist were 3–5%. These results were conﬁrmed by
Danish registries including more than 130.000 patients with
atrial ﬁbrillation: the combination of aspirin and vitamin K
antagonists signiﬁcantly increased the bleeding risk without
yielding an additional beneﬁt for stroke reduction compared
with vitamin K antagonists only [8]. Bleeding leads to
an increase in cardiovascular events and death, and this
interactioniscomplexandattributabletoseveralreasons:for
instance, antiplatelet therapy is more likely to be withdrawn
in patients with bleeding complications, thereby increas-
ing the risk of subsequent cardiovascular events, blood
transfusions might be directly harmful, and an increase in
immatureplateletsmightcontributetoaprothromboticstate
[9]. In addition, the variable pharmacodynamic response
to clopidogrel and narrow therapeutic window of vitamin
K antagonists are relevant disadvantages which might be
reduced in new drugs with a more predictable level of P2Y12
inhibition or anticoagulation [9].
Several prospective studies are currently conducted to
assess the use of dual and triple therapy in patients with
atrial ﬁbrillation after stent implantation. The MUSICA-
2 trial (NCT01141153) compares dual antiplatelet ther-
apy (aspirin 300mg/day + clopidogrel 75mg/day) with a
triple regimen (Acenocoumarol + aspirin 100mg/day +
Clopidogrel 75mg/day) in patients with atrial ﬁbrillation
and a low-to-moderate risk of stroke (CHADS ≤ 2) who
are undergoing coronary stent implantation. The study is
estimated to be completed in December 2012 with about 300
enrolled patients [10]. The ISAR Triple trial (NCT00776633)
examines 600 patients on oral anticoagulation who undergo
drug eluting stent implantation with concomitant aspirin
and clopidogrel medication for either a short duration of
6 weeks or a longer duration of 6 months; the study is
estimated to be completed in July 2012.
In addition, further issues to reduce both thromboem-
bolic as well as bleeding complications (such as radial versus
femoral access site) are addressed in a consensus document
of the European Society of Cardiology Working Group on
Thrombosis and the European Association of Percutaneous
Cardiovascular Interventions [11].
In clinical practise, especially two aspects of the ESC
guidelines for atrial ﬁbrillation might pose a challenge to
physicians. (1) Oral anticoagulation is recommended for the
majority of patients with atrial ﬁbrillation, and especially
a triple therapy with concomitant antiplatelets dramatically
increases the risk of bleeding in individual patients. On the
other hand, dual antiplatelet therapy after stent implantation
is necessary to reduce the risk of an often fatal stent throm-
bosis. (2) Lifelong oral anticoagulation without concomitant
antiplatelet therapy is recommended one year after stent
implantation after acute coronary syndrome. Because of an
annual rate of late stent thrombosis of about 0.6% even
with antiplatelet therapy and the limitations of vitamin K
antagonists to prevent stent thrombosis, a cautious approach
to complete termination of antiplatelet therapy seems war-
ranted [12, 13]. The American College of Chest Physicians
guidelines from 2008 recommend the combined use of
aspirin and vitamin K antagonists in patients after coronary
stentimplantationandanindicationfororalanticoagulation
as long-term treatment [14]. Although numerous studies
have demonstrated the beneﬁt of vitamin K antagonists
in coronary artery disease and the ESC guidelines on ST-
elevation myocardial infarctions from 2008 approve the
replacement of aspirin by a vitamin K antagonist in patients
with atrial ﬁbrillation, most studies were performed before
the use of drug eluting stents [15]. The ESC guidelines on
myocardial revascularisation from 2010 do not address this
topic.
The duration of clopidogrel after stent implantation has
also been much debated. Although the use of clopidogrel
for 6–12 months after drug eluting stent implantation is
long enough for most patients, an observational study points
at a possible beneﬁt of an extended use of clopidogrel
for more than 12 months in patients receiving a drug
eluting stent [16]. The recently published EXCELLENT trial
(Six-Month versus Twelve-Month Dual Antiplatelet Therapy
after Implantation of Drug-Eluting Stents) demonstrated4 Thrombosis
a superiority of 12 months of dual antiplatelet therapy com-
pared with 6 months in a subgroup of diabetic patients [17].
Currently,thePRODIGYstudylooksattheuseofclopidogrel
for 6 or 24 months in a broad all-comer patient population
receiving bare metal and drug eluting stents [18].
The ACTIVE-A trial (eﬀect of clopidogrel added to
aspirin in patients with atrial ﬁbrillation) assessed the
combined therapy of aspirin and clopidogrel in patients with
atrial ﬁbrillation who were considered unsuitable for therapy
with vitamin K antagonists [19]. Patients on the combined
therapy with clopidogrel and aspirin suﬀered signiﬁcantly
less often from stroke, albeit at the cost of increased bleeding
rates. These results were considered in the 2011 update on
the American guidelines (ACCF, AHA, and HRS) on atrial
ﬁbrillation, resulting in a class IIb recommendation for the
combined use of clopidogrel and aspirin in patients who
are considered unsuitable for vitamin K antagonist therapy
[20]. However, the combination of aspirin and clopidogrel
does poorly when compared to warfarin: the ACTIVE-W
trial (atrial ﬁbrillation clopidogrel trial with irbesartan for
prevention of vascular events) compared clopidogrel plus
aspirin with oral anticoagulation with warfarin in patients
with atrial ﬁbrillation and an increased risk for stroke. This
trial demonstrated a reduction in vascular events in patients
on warfarin without an increase in bleeding complications
[21].
Many components of the CHA2DS2-Vasc-Score are also
risk factors for atherosclerosis, and a high CHA2DS2-Vasc-
Score can identify both patients with a high risk for stroke
as well as patients with a high risk for ischemic heart
disease [15]. Antiplatelet therapy or anticoagulation is thus
often warranted both because of an increased stroke risk
as well as an increased risk for cardiac events. Vitamin
K antagonists may not provide a suﬃcient protection for
cardiac and embolic events in patients who are not within
the therapeutic range. One could speculate that this problem
might be diminished by the use of new drugs for oral
anticoagulation, for instance, dabigatran, rivaroxaban, or
apixaban. Dabigatran is a direct thrombin inhibitor and
rivaroxaban and apixaban inhibit factor Xa. However, in the
RELYtrial,anonsigniﬁcantincreaseinmyocardialinfarction
was observed in patients receiving dabigatran compared to
warfarin [22].
So current ESC guidelines might lead to an increased
risk of late stent thrombosis and insuﬃcient protection of
cardiaceventsinpatientswithpoorINRcontrol.Inaddition,
the use of dabigatran as monotherapy might not be a good
alternative in these patients. In contrast, fewer patients
receiving apixaban had a myocardial infarction than those
receiving warfarin in the ARISTOTLE study or aspirin in the
AVERROES trial [23, 24]. In the ROCKET-AF study, a sta-
tistically not signiﬁcant lower rate of myocardial infarction
was observed in patients receiving rivaroxaban compared to
placebo [25]. Thus, the use of apixaban or rivaroxaban or
a combination of low-dose dabigatran and aspirin might be
a good long-term alternative to vitamin K antagonists in
patients with atrial ﬁbrillation after stent implantation.
4. New Drugs for Oral Anticoagulation
After decades of research novel agents for oral anticoagu-
lation have ﬁnally been introduced into the market. New
drugs for oral anticoagulation include the direct thrombin
inhibitor dabigatran etexilate as well as the factor Xa
inhibitors rivaroxaban, apixaban, and edoxaban. The direct
thrombin inhibitor ximelagatran was only available for a
short period of time and taken from the market due to
liver toxicity. Vitamin K antagonists interfere with the bio-
syntheses of coagulation factors and thus achieve eﬀective
levels of anticoagulation only after several days, and their
eﬀect diminishes slowly after withdrawal. In contrast, direct
thrombin inhibitors and factor Xa inhibitors provide a suﬃ-
cient anticoagulant eﬀect within a few hours and their
eﬀects diminish fast. Further essentials of the new oral
anticoagulants include a wide therapeutic window, little
interaction with food intake, and other drugs compared to
vitamin K antagonists. The cumbersome monitoring of the
anticoagulation eﬀect associated with vitamin K antagonists
isthusnotnecessaryanymoreinpatientsreceivingthesenew
substances. The problems of dosing of vitamin K antagonists
result in a high percentage of inadequate anticoagulation
levels: even in the setting of clinical trials, the overall time
withininthetherapeuticrangeisoften<70%.Possibledisad-
vantages of the new substances include the lack of antidotes,
diﬃculties in eﬀect monitoring, and the short half-life that
might pose a problem in patients with low compliance.
Recently, several large studies have demonstrated a beneﬁt of
thenew oralanticoagulantscomparedtowarfarinin patients
with atrial ﬁbrillation.
The RELY study included more than 18.000 patients
with atrial ﬁbrillation and a mean CHADS2-score of 2.1
randomized to dabigatran 110mg bid, dabigatran 150mg
bid,orwarfarin[22].Thehighdoseofdabigatranledtoasig-
niﬁcantdecreaseinstrokeandsystemicembolismwithoutan
increase in major hemorrhage. Mortality was also reduced,
although not reaching statistical signiﬁcance. Dabigatran
applied in a low dose resulted in a signiﬁcant decrease in
major hemorrhage without an increase in ischemic stroke.
The net clinical beneﬁt (consisting of stroke and systemic
embolism,majorhemorrhageandmortality)wasbestforthe
group of patients with dabigatran 150mg bid. However, fatal
bleedings especially in older patients and in patients with
an impaired renal function have been reported in patients
receiving dabigatran. Indeed, a recent subgroup analysis
of the RELY trial showed that patients ≥ 75 years had a
similar or higher bleeding risk on dabigatran compared with
warfarin, and renal function should be assessed yearly in
patients ≥ 75 years as well as in clinical situations with a
possible decline in renal function [26].
In the ARISTOTLE study, also more than 18.000 patients
with atrial ﬁbrillation and a mean CHADS2-score of 2.1
were included [23]. The study demonstrated a superiority
of apixaban versus warfarin with a reduction in stroke
and systemic embolism. In addition, apixaban caused less
bleeding and resulted in a lower mortality.
The ROCKET-AF study included more than 14.000
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a noninferiority of the factor Xa inhibitor rivaroxaban com-
pared to warfarin for the prevention of stroke or systemic
embolism [25]. There was no diﬀerence in the risk of major
bleeding, although fatal and intracranial bleeding occurred
less frequently in the rivaroxaban group. In contrast to
the RELY and ARISTOTLE study, a superiority of the
new drug in the primary endpoint was not seen in the
intention-to-treat population but only in the on-treatment
population, although patients in the ROCKET-AF study
had a higher mean CHADS2 score of 3.5 resulting in higher
event rates than patients in the RELY and ARISTOTLE study.
However, a potential beneﬁt of rivaroxaban is the once-daily
dose compared to the twice-daily intake of apixaban and
dabigatran. In addition, a trend towards a higher risk of
myocardial infarctions was seen in patients on dabigatran
compared with warfarin, whereas this was not observed for
rivaroxaban in the ROCKET-AF trial. Indeed, the ATLAS
ACS 2-TIMI 51 demonstrated ad reduction in mortality
in patients after acute coronary syndrome on low-dose
rivaroxaban (2.5mg bid) at the cost of higher bleeding
complications [27].
The safety and eﬃcacy outcomes of the RELY, ROCKET-
AF, and ARISTOTLE study are depicted in Figure 1.
The oral factor Xa-inhibitor edoxaban is currently being
tested in patients with atrial ﬁbrillation in the Engage AF
TIMI 48 study (NCT00781391) as well as in a Chinese
study (NCT00806624). In addition, an international study
with a short follow-up of 3 months is assessing bleeding
complications (NCT00504556).
5. New Drugs for Oral Anticoagulation in
Combination withAntiplatelet Therapy
The results of the three large studies RELY, ARISTOTLE,
and ROCKET-AF are very promising. Concomitant use of
antiplatelet therapy in patients with atrial ﬁbrillation who
need oral anticoagulation is common in clinical practice
and was seen in about one third of the patients in these
three studies. However, concomitant antiplatelet therapy
in patients on warfarin due to atrial ﬁbrillation increases
the risk of hemorrhage: the combination of warfarin and
aspirin is associated with an almost twofold bleeding risk
and the combination of warfarin and clopidogrel or a triple
therapy consisting of warfarin, aspirin, and clopidogrel with
a threefold bleeding risk compared to warfarin monotherapy
[28]. Data from prospective trials looking at the beneﬁt
and risk of combining oral factor Xa-inhibitors or direct
thrombin inhibitors with antiplatelet therapy as a dual or
tripletherapyaremissing.However,apost-hocanalysisfrom
the RELY study has been published as an abstract, and a
subgroup analysis is reported in the ARISTOTLE study.
In the ARISTOTLE study, 31% of the patient received
concomitant aspirin medication and a low-percentage
(1.9%) clopidogrel. In the subgroup analysis, there was no
signiﬁcant diﬀerence between patients receiving aspirin at
randomization and those who did not with regard to stroke
and major bleeding (P = 0.4 for interaction) [23]. 36% of
the ROCKET-AF study population received concomitant
aspirin therapy, up to now a subgroup analysis has not been
published [25].
In the RELY study, almost 7000 patients (40% of the
study population) received concomitant aspirin or clopi-
dogrel. In accordance with the results of the main study,
a post-hoc analysis showed that dabigatran 110mg bid
was noninferior to warfarin with regard to stroke and sys-
temic embolism and superior to warfarin in terms of bleed-
ing independent of a concomitant antiplatelet therapy. Dabi-
gatran 150mg bid was superior to warfarin with regard to
stroke and systemic embolism, especially among patients
without concomitant use of antiplatelet therapy (HR =
0.52, 95% CI: 0.38–0.72). This eﬀect seemed to be reduced
in patients with concomitant antiplatelet therapy (HR =
0.80; 95% CI: 0.59–1.08), although the diﬀerence was not
statistically signiﬁcant (P for interaction = 0.06). Dabigatran
150mg bid was similar to warfarin in terms of bleeding
complicationsregardlessofconcomitantantiplatelettherapy.
The rates of major bleeding increased by 60% in patients on
concomitantantiplatelettherapy(HR =1.60,95%CI =1.41–
1.81 after adjustment for age, gender, warfarin experience,
systolic blood pressure, coronary artery disease, heart failure,
hypertension, diabetes, prior TIA, creatinine clearance, and
statin use) [29].
In conclusion, in patients who require dual or triple
therapy, low-dose dabigatran or apixaban might be a good
alternative to warfarin due to good eﬃcacy and rather low
bleeding complications. However, current data supporting
this are scarce. A prospective randomized trial would be
sensible but is unlikely to be conducted.
6.PAR-1 Receptor Antagonists
The protease-activated receptor-1 (PAR-1) thrombin recep-
tor antagonists atopaxar and vorapaxar represent a novel
approach to the inhibition of platelet activation. Thrombin
can stimulate platelet activation via the PAR-1 receptor on
the platelet surface, and PAR-1 thrombin receptor antago-
nists can thus reduce thrombin-induced platelet activation.
In contrast, aspirin and P2Y12 receptor antagonists do
not interfere with PAR-1-dependent platelet activation, and
patients on dual antiplatelet therapy remain at risk of
cardiovascular events because of alternative pathways of
platelet activation [30].
The oral PAR-1 receptor antagonist vorapaxar is being
evaluated in two phase III trials. However, the Trial to
Assess the Eﬀects of SCH 530348 in Preventing Heart Attack
and Stroke in Patients with Acute Coronary Syndrome
(TRACER) was stopped early; and vorapaxar was stopped
in patients with a history of stroke in the Trial to Assess the
Eﬀects of SCH 530348 in Preventing Heart Attack and Stroke
in Patients with Atherosclerosis (TRA 2◦P-TIMI 50) due to
anexcessofintracranialhemorrhage[30,31].Thetrialisstill
ongoing for patients with a history of myocardial infarction
or peripheral arterial disease.
The oral PAR-1-receptor antagonist Atopaxar has a
shorter half-life than vorapaxar and has been tested in the
phase II Lessons from Antagonizing the Cellular Eﬀects of6 Thrombosis
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Figure 1: GI: gastrointestinal, ICH: intracerebral hemorrhage. Eﬃcacy and safety outcomes in RELY, ARISTOTLE and ROCKET-AF [22,
23, 25]. Results are displayed for Dabigatran 150mg bid.
Thrombin (LANCELOT)-ACS trial. This trial demonstrated
the safety and tolerability of atopaxar in patients with acute
coronary syndrome and also displayed a trend towards a
lower incidence of cardiovascular death, myocardial infarc-
tion, and stroke accompanied with a nonsigniﬁcant increase
in the rate of bleeding [30]. This trial was conducted in
parallel with the LANCELOT CAD trial, a phase II trial with
patients with stable coronary artery disease [32]. In this trial,
the use of atopaxar resulted in more minor bleeding and a
trend towards fewer ischemic events.
Atopaxar might have a diminished risk of bleeding
compared with traditional antithrombotic drugs as it selec-
tively reduces thrombin-mediated platelet activation but
does not disrupt thrombin-dependent ﬁbrin generation or
ADP-dependent platelet activation [30].
However, the eﬃcacy and safety of atopaxar need to be
proven in large phase III trials. With regard to vorapaxar, the
excess rate in intracranial bleeding is sobering. No clinical
data exist with regard to the combination of PAR-1 with
warfarin or new anticoagulant drugs.
7. Further Strategies for
Bleeding Risk Reduction
Several strategies apart from the choice of antiplatelet
therapy and oral anticoagulation can reduce the risk of
bleeding in patients with atrial ﬁbrillation and coronary
stenting.Astripletherapydramaticallyincreasesthebleeding
risk, the duration of triple therapy should be limited to
a minimum. Balloon angioplasty or the use of bare metal
stents opposed to drug eluting stents can reduce the time of
clopidogrel medication and should be preferred in patients
requiring triple therapy [33]. In addition, during triple or
dual therapy, the INR should be aimed at 2–2.5 rather than
2-3. The choice of access site for coronary interventions also
hasimplicationsonthebleedingrisk:radialaccess,whichcan
also be performed in acute myocardial infarction, is associ-
ated with lower bleeding complications than a femoral access
[34]. Peri-interventional antithrombotic therapy also aﬀects
bleeding complications, and favourable results have been
observed for bivalirudin instead of unfractionated heparin
in combination with a glycoprotein IIb/IIIa-inhibitor [35]. A
proton pump inhibitor can reduce the risk of gastrointestinal
bleeding in selected patients [36].
8. Conclusion
An individualized approach is needed for patients with
atrial ﬁbrillation and coronary artery disease to ﬁnd the
ﬁne balance between the risk of cerebrovascular events and
bleeding complications. Scores like the CHA2DS2-Vasc and
the HAS-BLED score can help to deﬁne the need for oral
anticoagulation and assess the bleeding risk in individual
patients, and the ESC guidelines on atrial ﬁbrillation provide
a detailed suggestion for the combination of anticoagulation
and antiplatelet therapy. However, these recommendationsThrombosis 7
are mainly based on expert opinion and data derived from
large prospective studies are lacking. The ESC guidelines
on atrial ﬁbrillation recommend a triple therapy consisting
of aspirin, clopidogrel, and oral anticoagulation after stent
implantation in patients with atrial ﬁbrillation requiring
oral anticoagulation. This poses patients at an increased risk
for bleeding complications, and this problem might even
be aggravated with the use of novel antiplatelets such as
prasugrel or ticagrelor. On the other hand, monotherapy
with oral anticoagulation is recommended for patients with
stable coronary artery disease and atrial ﬁbrillation; possibly
increasing the risk of cardiac events.
New drugs for oral anticoagulation, especially apixaban
and dabigatran, have shown convincing results in large
clinical trials compared to warfarin. Although detailed
data on patients with coronary artery disease receiving
antiplatelets and novel anticoagulants are missing, especially
the use of apixaban or low-dose dabigatran might be
a good alternative to warfarin by possibly reducing the
risk of bleeding (which is especially high in patients on
triple therapy). In addition, especially apixaban—possibly
in combination with aspirin—might also be a very good
alternative to warfarin monotherapy in patients with stable
coronary artery disease and atrial ﬁbrillation. However, it
has to be taken into account that data on the combination
of aspirin and dabigatran or apixaban are all derived from
subgroup analyses.
An individualized approach taking into account the
individualriskofstroke,bleeding,myocardialinfarction,and
stent type is needed to assess the best treatment option, and
hopefully new drugs will help to increase both eﬃcacy and
safety of the treatment.
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